ropinirole arw ropinirole (as hydrochloride) 2mg tablet blister pack
arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 2.28 mg (equivalent: ropinirole, qty 2 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; laureth-8 - repreve is indicated for the treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.
ropinirole arw ropinirole (as hydrochloride) 0.5 mg tablet blister pack
arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 0.57 mg (equivalent: ropinirole, qty 0.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; iron oxide yellow; iron oxide red; laureth-8 - repreve is indicated for the treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.
ropinirole arw ropinirole (as hydrochloride) 0.25mg tablet blister pack
arrotex pharmaceuticals pty ltd - ropinirole hydrochloride, quantity: 0.285 mg (equivalent: ropinirole, qty 0.25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - repreve is indicated for the treatment of primary restless legs syndrome, including the reduction of associated periodic limb movement and episodes of nocturnal arousal.
ropinirole hydrochloride tablet, film coated
ncs healthcare of ky, inc dba vangard labs - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole tablets areindicated for the treatment of parkinson’s disease. ropinirole tablets areindicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole tablets in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were admini
ropinirole hydrochloride tablet, film coated
major pharmaceuticals - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole tablets are indicated for the treatment of parkinson’s disease. ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole tablets in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were ad
ropinirole hydrochloride tablet, film coated
cardinal health 107, llc - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole tablets are indicated for the treatment of parkinson’s disease. ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole tablets in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were ad
ropinirole hydrochloride tablet film coated extended release
mylan pharmaceuticals inc. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 2 mg
ropinirole hydrochloride tablet film coated extended release
avera mckennan hospital - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 8 mg
ropinirole hydrochloride tablet film coated
bryant ranch prepack - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg
ropinirole hydrochloride tablet film coated
avera mckennan hospital - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg